Healthcare ❯Pharmaceuticals
Acquisitions Pharmaceuticals Drug Development Drug Development Shareholder Value Sales Projections Investment Strategies Equity Markets Corporate Finance Drug Development
The deal strengthens Merck’s oncology pipeline with two approved rare-disease therapies and is projected to boost earnings by 2027.
